TCR Engineered T-Cell Therapy Market Report 2018: An Industry Analysis of Technologies, Pipelines, Stakeholders & Deals - ResearchAndMarkets.com
Jun. 06, 2018
DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The "TCR Engineered T-Cell Therapy 2018: An Industry Analysis of Technologies, Pipelines, Stakeholders & Deals" report has been added to ResearchAndMarkets.com's offering.
This report, "TCR Engineered T-Cell Therapy 2018: An Industry Analysis of Technologies, Pipelines, Stakeholders & Deals" published in May 2018 brings you up-to-date regarding key TCR-T players, key TCR-T technologies and product candidates, business models, deals and funding opportunities.
The report analyzes the TCR-T pipelines and stakeholders in the field, especially focused and diversified TCR-T companies and their relationship with academia and major pharma/biotech. The report highlights the value of TCR-T assets in terms of partnering economic conditions, acquisition prices and financing rounds.
T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cutting edge of adoptive T-cell therapy. Both receptors deploy T-cells to target the tumor, but CAR T-cells (CAR-T) are limited to binding to cell surface antigens, while TCR T-cells (TCR-T) recognize peptides (derived from intracellular proteins) presented on the cell surface by the major histocompatibility complex (MHC) class I.
TCR-Ts have so far operated in the shadow of CAR-Ts, but may have the advantage in solid tumors. The first approved CD19-specific CAR-Ts are indicated for hematologic malignancies, but CAR-Ts were less successful against solid tumors.
Key questions answered:Which targets are chosen for development of TCR-Ts? How close are neoantigen-specific TCR-Ts to the clinic? Which technologies are used for generation of T-Cell Receptors? Has clinical proof-of-concept been shown for any TCR-T? How does the TCR-T pipeline look like? What manufacturing strategies and solutions have companies chosen? Are next generation TCR-Ts already in development? What are the key technologies for a successful TCR-T? Who are the key players in the TCR-T field? How tough is competition among TCR-T developers? Should companies be focused on TCR-Ts only or be diversified into various adoptive T-cell therapeutics? Which technologies and assets attract licensees? How is the financing situation for TCR-T? What are the key success factors for TCR-Ts?
Key Topics Covered:
1 Executive Summary
2 Introduction, Overview & Background
3 Technologies 3.1 Overview & Discussion 3.2 Technologies for Discovery of Targets for TCRs 3.3 Technologies for TCR Discovery 3.4 TCR Engineered Allogeneic T-Cells 3.5 Next Generation Technologies to Improve Safety & Efficacy
4 Pipeline 4.1 Overview & Discussion 4.2 Profiles of MAGE-A Specific TCR T-Cells 4.3 Profiles of NY-ESO-1 Specific TCR T-Cells 4.4 Profiles of AFP Specific TCR T-Cells 4.5 Profiles of PRAME Specific TCR T-Cells 4.6 Profiles of WT1 Specific TCR T-Cells 4.7 Profiles of Other Target Specific TCR T-Cells 4.8 Profiles of Neoantigen Specific TCR T-Cells
6 Companies 6.1 Company Overview & Discussion 6.2 Pure Play TCR T-Cell Companies 6.3 Profiles of Diversified Companies with TCR-T Activities 6.4 Other Companies with TCR-T Activities
7 Business Development & Financing 7.1 Role of academia for the TCR-T industry 7.2 Role of Big Pharma & Biotech for TCR-T 7.3 Technology In-Licensing Deals 7.4 Collaborative Arrangements 7.5 Acquisitions of Companies and Assets 7.6 Financing of TCR-T Companies
8 Outlook & Perspectives
Companies MentionedAdaptimmune Adicet Bio Aeon Therapeutics Shanghai AgenTus Therapeutics Alpine Immune Science Atreca Bellicum Pharmaceuticals BioNTech Bluebird bio Cell Medica CRISPR Therapeutics Editas Medicine Eureka Therapeutics Gadeta GlaxoSmithKline Immatics ImmunoCellular Therapeutics Intellia Therapeutics Juno Therapeutics/Celgene Kite Pharma/Gilead Sciences Lion TCR Medigene Neon Therapeutics Regeneron Pharmaceuticals Sangamo Therapeutics Tactiva Therapeutics Takara Bio TC BioPharm TCR2 Therapeutics Tmunity Therapeutics Universal Cells Zelluna Immunotherapy ZIOPHARM Oncology
For more information about this report visit https://www.researchandmarkets.com/research/lbzlhj/tcr_engineered?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005577/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/06/2018 06:18 AM/DISC: 06/06/2018 06:18 AM